Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours

Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors

(2010) Atsutaka Noguchi et al.   CYTOTHERAPY

Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies

(2009) J. Gertner-Dardenne et al.   BLOOD

Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma

(2009) Yu Abe et al.   EXPERIMENTAL HEMATOLOGY

IL-21-Mediated Potentiation of Antitumor Cytolytic and Proinflammatory Responses of Human V 9V 2 T Cells for Adoptive Immunotherapy

(2009) A. Thedrez et al.   JOURNAL OF IMMUNOLOGY

Efficient Killing of Human Colon Cancer Stem Cells by    T Lymphocytes

(2009) M. Todaro et al.   JOURNAL OF IMMUNOLOGY

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

(2008) Jaafar Bennouna et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Zoledronate facilitates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy*

(2008) M. Kondo et al.   CYTOTHERAPY

Inhibition of phosphoantigen-mediated γδ T-cell proliferation by CD4+ CD25+ FoxP3+regulatory T cells

(2008) Volker Kunzmann et al.   IMMUNOLOGY

Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—Rituximab and trastuzumab

(2008) Hirotake Tokuyama et al.   INTERNATIONAL JOURNAL OF CANCER